Free shipping on all orders over $ 500

GDP366

Cat. No. M13557

All AbMole products are for research use only, cannot be used for human consumption.

GDP366 Structure
Size Price Availability Quantity
1mg USD 235  USD235 In stock
5mg USD 525  USD525 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells.

Chemical Information
Molecular Weight 375.45
CAS Number 501698-03-9
Solubility (25°C) DMSO 62.5 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Jorge Antonio Elias Godoy Carlos, et al. Invest New Drugs. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis

[2] Xianping Shi, et al. Cancer Biol Ther. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells

Related Survivin Products
LQZ-7I

LQZ-7I is a novel selectively inhibitor of survivin dimerization with IC50s of 4.8 µM and 3.1 µM in prostate cancer cell lines PC-3 and C4-2, respectively. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors.

YM155

YM155 (Sepantronium Bromide) is a novel small molecule that suppresses transactivation of survivin through direct binding to its promoter.

  Catalog
Abmole Inhibitor Catalog




Keywords: GDP366 supplier, Survivin, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.